Life Sciences Archive » July, 2010

Life Sciences - July, 2010

186 articles

• GSK 'Triple Protection' Trademark Too Generic: Colgate
• FDA Links Cubicin To Serious Strain Of Pneumonia
• Study Finds Avandia, Actos Linked To Fractures
• Sandoz Drops Generic Mirapex Plans For Now
• Limits To 'Pass-On' Defense May Up The Ante In Calif.
• Fed. Circ. Won't Rehear Prandin Use Code Patent Case
• Sen. Panel Advances Ban On Pay-For-Delay Deals
• Plaintiffs Lose Class Cert. Bid in Mo. Neurontin Case
• FDA Uncovers Violations At Sanofi Vaccine Plant
• Judge OKs Smith & Nephew Letters About Patent Suit
• Fed. Circ. Tosses Becton's $58M Syringe Patent Win
• Monsanto, Pfizer Move PCB Action To Federal Court
• Australia Clears Novartis' Alcon Buy With Conditions
• FDA's Drug Ad Rule And Learned Intermediary Doctrine
• Cephalon, Mylan Drop Patents From Nuvigil Dispute
• Pricing Conduct Beyond The Safe Harbor
• Botched Plea Leads To Retrial In Zoloft Murder Case
• College Fails To Get More Royalties From Merck Drug
• Nufarm To Sell Assets To Settle FTC Merger Worries
• Investors Resurrect Fraud Suit Over Nixed Sanofi Drug
• Double-Patenting Dooms Lilly's Gemzar IP: Fed. Circ.
• Wyeth Wins Round 2 In Trio Of Fen-Phen Suits
• Kirkland Reps Vestar in $294M Deal for HealthGrades
• Bausch & Lomb Recalls Eye Vitamins Over Gel Design
• Federal Law Applies In Cordis Stent Case: NJ Court
• NJ Law To Apply In Malicious Prosecution Suit V. Biovail
• Mannatech Supplement Patent Suit Stays In Texas
• St. Jude Goes After Volcano Over Guide Wire Patents
• Genzyme Sues Roxane Again Over Generic Hectorol
• Avandia Panelist Issue Sent To HHS Inspector General
• FTC Gaining High Ground In Pay-For-Delay Fight: Chair
• Dewey & LeBoeuf IP Trio Head To Kaye Scholer
• Orion, Sun Settle Patent Spat Over Parkinson's Drugs
• Sanofi Loses Suit Against FDA Over Generic Eloxatin
• FTC Thinks Rules Don't Apply To It: Watson CEO
• FCC, FDA Team Up On Wireless Medical Device Rules
• Servier Gave False Info During Pharma Probe: EU
• Wyeth Bests Pa. Fen-Phen Hypertension Suit
• MDL Over Pfizer's Neurontin Soon To Be 46 Cases Lighter
• Qui Tam Plaintiff's Claims Against Forest Labs Survive
• Purdue, King End Spat Over Less Addictive Painkillers
• Limiting Pass-On Defense In Calif. — With Exceptions
• Mylan Hit With Patent Suit Over FazaClo ANDA
• FDA Panel Rejects Plan To Curb Opioid Abuse
• FOIA Request Shows GSK Touted Off-Label Avodart Use
• Exergen Escapes False Marking Suit Due To Overlap
• How To Gain An Edge When Bringing A Daubert Motion
• Plaintiffs Atty Appeals Ban From AWP Cases
• Medicis, Mylan Settle Suits Over Acne Drug
• Boston Scientific Warns Of More Defibrillator Problems
• Senate Strips Pay-For-Delay Ban From Spending Bill
• FTC Denies Violations In Watson Pay-To-Delay Probe
• Forest, Merz Wrap Up Namenda Patent Litigation
• Novartis Offers EU Antitrust Fixes For Alcon Merger
• GAO Blasts Gene Test Cos. For Misleading Marketing
• Investors' Fraud Suit Against ArthroCare Trimmed
• EU Regulatory Procedures In The Pharmaceutical Sector
• Boehringer Hit With New OT Action Over Sales Reps
• Cisco, KV Targeted In False Marking Suits
• Lannett Sues Over FDA Morphine Warning Letter
• FDA Panel Favors Nixing Avastin For Breast Cancer
• Aetna Loses Bid To Intervene In Wellbutrin Suit
• FDA Warns Abbott Unit Over Glucose Monitors
• Alcon Recalls Constellation Eye Surgery System
• FDA Bars New Patients From Avandia Study
• Claims Cut From Suit In Hydroxycut Marketing MDL
• Suits Pile Up In Zimmer Hip Device MDL
• AntiCancer, CRI Settle Cancer Tracker Patent Suits
• The Opt-Out Decision In Price-Fixing Cases
• Pfizer Gets Off-Label Suit Over 12 Drugs Tossed
• Teva Agrees To End IP Suit Over Aricept Patent
• Recession Takes Bite Out Of GC Bonuses
• Public Health Groups Fight USTR Special 301 Program
• Alpharma Sales Reps Exempt From OT: Judge
• Pro-Avandia FDA Panelist Is Paid GSK Speaker
• J&J Hit With Grand Jury Subpoena Over Drug Recalls
• 5th Circ. Shoots Down Challenge To Vioxx Settlement
• Novartis Wins Punitive Damages Ruling In Aredia Suits
• FDA Finds Violations At Pa. J&J Plant
• Pfizer, Abbott, Others Hit With False Marking Suits
• Valeant Hit With Shareholder Suit Over $3B Biovail Deal
• Validity Of Pfizer's Protonix Patent Upheld
• Neutrogena False Ad Ruling Sticks In Sunscreen Spat
• J&J Gets SFF To Stop Selling Dodgy Glucose Strips
• Court Spares Part Of Kickback Suit Against Abbott
• Teva, Novartis End Patent Spat Over Zometa
• Bayer Sues To Halt Lupin From Making Generic Yaz
• Plaintiffs Want Rader Recusal In Gene Patent Case
• Patent Claims Ruling For Wyeth Sticks In Effexor Suit
• Sonnenschein Woos LeClairRyan IP Litigation Head
• King Pharma Sues Sandoz Over Generic EpiPen
• Elan Inks $204M Deal In Zonegran Off-Label Probe
• Is Burying A Material Reference Inequitable Conduct?
• Okla. Wants In On Wyeth Protonix Medicaid Suits
• Genzyme Sues Lupin Over Generic Renvela Powder
• Gilead Targets Lupin Over Generic Ranexa
• Taro Pharma's Suit To Block Sun Takeover Tossed
• GSK Ponied Up $2.4B In Legal Charges In 2nd Quarter
• Lawyers Push For Top Spots In Avandia MDL
• Latham Reps Carlyle Group In $3.8B NBTY Acquisition
• Iovate To Pay FTC $5.5M In False Health Claims Suit
• Cravath Reps Mylan In $550M Bioniche Purchase
• GSK Settles 10,000 Avandia Cases For $460M
• Watson CEO OK'd To Quiz FTC In Subpoena Dustup
• Cert. Denied, For Now, In Flonase Antitrust Suit
• Novartis Reps Strike $175M Deal To End Sex Bias Case
• Novo Hit With Another Monopoly Suit Over Prandin
• Mass. AG Escapes Sanctions In Medicaid Fraud Suit
• House Hearing Probes Drug Limits In Meat Farming
• FDA Panel Votes To Restrict GSK's Avandia
• Pfizer Faces Shareholder Suit Over $2.3B Settlement
• Abbott Settles Syringe Action Right Before Jury Verdict
• Novartis, Baxter Dismissed From Medicare Rebate Suit
• Zoll Hits Philips With Patent Suit Over Defibrillators
• Patent Suit Plaintiffs Lose Ground At Fed. Circ.
• MedIdea Seeks Rehearing Of Patent Suit Transfer
• Polio Vaccine Suit Against Pfizer, Others Dismissed
• The Role Of Cross-Border E-Discovery In The BP Crisis
• FTC Demands More Info On $1.6B Charles River Deal
• Confusion Abounds For Big Pharma After EU Astra Ruling
• Calif. High Court Nixes 'Pass-On' Defense
• Apotex Eyes Generic Version Of Cephalon's Nuvigil
• FocusFactor Distributors Falsely Marked Product: Suit
• Plaintiffs Attorneys Find FLSA Ally In DOL
• CB Fleet Settles Bowel Cleanser Product Liability MDL
• Medtronic Faces False Marking Suit Over Stents
• Securities Filings Drop Sharply As Credit Crisis Subsides
• McDermott Snags Former FDA Bigwig From Buchanan
• Genzyme Sues Watson Over Renvela Powder ANDA
• Pharmacy Benefit Manager Law Preempted: DC Circ.
• Caliper Life Sued Over Animal Imaging Patent
• Cravath, Weil Advise J&J On $480M Micrus Purchase
• Consumers Target J&J Over Children's Drug Recalls
• 2nd Circ. Novartis Ruling Muddies Sales Rep OT Issue
• Russian Antitrust Watchdog Targets Novo Nordisk
• Why Daubert Makes Sense At Class Cert. Under Title VII
• 9th Circ. Remands First Republic Fraud Suit After Merck
• FDA Doctor Calls GSK Avandia Trial Biased
• Fosamax Victor's Lawyer Faces Sanctions For Closing
• 9th Circ. Chucks Beach Boy's Spat With UK Paper
• Gilead To Pay $8M To Settle Viread Securities Action
• Cadwalader Trial Pro To Help Lead Litigation Team
• Do You Really Want Grandfathered Health Plan Status?
• J&J Expands OTC Drug Recall Over Smell Issue
• Medical Groups Seek Action On Device Tracking Rule
• AMS, Laser Peripherals Settle Patent Dispute
• Alcon Forms $50M Trust For Novartis Shareholder Suits
• Shire Slaps Zydus With Suit Over Lialda ANDA
• Talecris Settles Jilted Job-Seeker FCRA Class Action
• Rx USA Hit With Sanctions Over Faked E-Mails
• Genzyme Fights To Keep Anika's Monovisc Out Of US
• Injunction On Apotex Reinstated In Fortical IP Suit
• Obama Touts Progress On Export Initiatives
• Merck, Sanofi Vaccine Deals Could Face FTC Probe
• Aspen Lowers Offer For Sigma To $552M
• Atty Hits Labaton Sucharow With OT Action
• Ev3 Inc. Settles Suits Over $2.6B Covidien Merger
• Novartis Challenges USPTO Patent Extension Policy
• Schering Settles With Supplier Over Recall Costs
• Senate Panel Probes $60M In Missing Medicare Claims
• FDA Warns Cornerstone Over Zyflo Marketing
• 9th Circ. Affirms Dismissal Of Cutera Investor Suit
• FDA Issues Class I Recall Of Medtronic Defibrillators
• Polish Health Attys Jump To Baker & McKenzie
• WilmerHale Snags Wyeth Bigwig For IP Team
• EU Report Shows Drop In Pay-For-Delay Deals
• Temp Nursing Giant MSN To Sell Assets To Creditors
• 2nd Circ. Finds Drug Reps Not Exempt From FLSA
• $44M Verdict Sticks In Dentsply Contract Spat
• Latham & Watkins Reps Eli Lilly In Alnara Acquisition
• Actavis, Sandoz Open Fire On Prandin Patent
• Wyeth Sues IPC To Stave Off Effexor Generic Bid
• Genzyme Sues Impax Over Generic Renvela Powder
• Calif. Moves Closer To Enacting BPA Ban
• The Power Of Procedure Under Anti-SLAPP Laws
• House Slips Pay-For-Delay Ban Into War Bill
• Ex-PDL Exec Can't Dodge MedImmune Subpoena
• Glenmark Slapped With Sanctions In Tarka ANDA Suit
• Drug Giants Face Congressional FCA Inquiry
• Enzo DNA Patent Suits Remain On Hold For High Court
• AsymmetRx Ends Cancer Test IP Suit Against Dako
• EU Court Backs Astra Antitrust Fine Over Patent Abuse
• Mannatech Rivals To Halt Sale Of Dietary Supplements
• Ex-Cravath Atty Now Top Lawyer For Morgan Stanley
• What Must An Inventor Do To Possess An Invention?
• UCL Class Actions In The Wake Of Tobacco II